Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O6SA
|
|||
| Drug Name |
KA2507
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Karus Therapeutics Oxfordshire, United Kingdom
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histone deacetylase 6 (HDAC6) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Alcoholism | |||
| Viral carcinogenesis | ||||
| Pathway Interaction Database | Signaling events mediated by HDAC Class II | |||
| Signaling events mediated by HDAC Class I | ||||
| Reactome | NOTCH1 Intracellular Domain Regulates Transcription | |||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | ||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | ||||
| Assembly of the primary cilium | ||||
| WikiPathways | Ectoderm Differentiation | |||
| Neural Crest Differentiation | ||||
| Cell Cycle | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.